Integrin αvβ6-targeted PET in Malignant Tumors

Inclusion Criteria: * Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer; * Age ≥18 years, regardless of gender; * No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT; * Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1; * Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study; * Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form. Exclusion Criteria: * Known allergy to injection or its excipients; * Severe liver or renal dysfunction; * Claustrophobia or other psychiatric disorders; * History of other malignant tumors; * Participation in another clinical trial within 30 days prior to PET/CT scan; * Pregnant or breastfeeding women; * Refusal to participate or request for withdrawing from the clinical study; * Other conditions deemed unsuitable for inclusion by investigator.